17:59 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

Opdivo misses survival endpoint in Phase III for SCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said Opdivo nivolumab missed the primary endpoint of improving overall survival (OS) in the Phase III CheckMate -331 trial to treat small cell lung cancer in patients who relapsed following platinum-based...
22:04 , Oct 12, 2018 |  BC Extra  |  Clinical News

Opdivo misses survival endpoint in Phase III for SCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said Opdivo nivolumab missed the primary endpoint of improving overall survival (OS) in the Phase III CheckMate -331 trial to treat small cell lung cancer in patients who relapsed following platinum-based...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Clinical News

Calsed amrubicin regulatory update

Dainippon submitted a regulatory application to China's State Food and Drug Administration (SFDA) for amrubicin as first-line treatment for small cell lung cancer (SCLC). Celgene has North American and European rights to the third-generation synthetic...
07:00 , Aug 23, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Topoisomerase I (TOP1); TOP2 In vitro and mouse studies suggest a class of dual inhibitors of TOP1 and TOP2 could help treat cancer. Chemical...
07:00 , Mar 19, 2012 |  BioCentury  |  Strategy

Incentivized success

Boston Biomedical Inc. 's story shows what can happen when researchers are given the imperative and the resources to invent as if their livelihoods depend on it. The company emerged from ArQule Inc. in 2006...
07:00 , Jul 4, 2011 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Stand and deliver

Several market cap bands tracked by BioCentury did well last quarter, as investors rewarded late-stage data and transformative deals. The NYSE Arca Biotechnology Index and the BioCentury 100 each gained 7% in 2Q, while the...
07:00 , May 23, 2011 |  BC Week In Review  |  Clinical News

Calsed amrubicin: Phase III data

The open-label, international Phase III ACT-1 trial in 637 patients showed that IV amrubicin as second-line therapy missed the primary endpoint of significantly improving OS vs. topotecan (7.5 vs. 7.8 months, p=0.17). Amrubicin also missed...
07:00 , May 23, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acorda Therapeutics Inc. (NASDAQ:ACOR) gained $3.67 (14%) to $30.38 on Friday, while partner Biogen Idec Inc. (NASDAQ:BIIB) was up $0.39 to $97.11, after EMA's CHMP reversed a prior decision and recommended conditional approval...
00:41 , May 20, 2011 |  BC Extra  |  Clinical News

Amrubicin misses in lung cancer

Second-line treatment with amrubicin from Celgene Corp. (NASDAQ:CELG) missed the primary endpoint of significantly improving overall survival vs. topotecan in the Phase III ACT-1 trial to treat small cell lung cancer (SCLC), according to an...
07:00 , Oct 4, 2010 |  BioCentury  |  Finance

4Q10 milestones

4Q10 milestones...